Poll results: Medical education falters on pain relief

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain.

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain. Of those who responded to ONI’s June poll question-“Do you feel your medical school education in pain relief and opioid pharmacology was adequate?”-71% answered in the negative. Only 14% said that their pain management training was adequate, while 16% said they weren’t sure.

Although the International Association for the Study of Pain has established guidelines for pain management, compliance is spotty, said Kathleen M. Foley, MD, of Memorial Sloan-Kettering Cancer Center, in New York.

The poll was linked to the article, “US cancer patients still plagued by undertreated pain” (June 2008, page 20). To respond to this month’s poll (on page 2), visit www.CancerNetwork.com.

Recent Videos
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Two experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
7 experts are featured in this series.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Related Content